Addressing an Unmet Medical Need in Urothelial Carcinoma
Christopher J. Hoimes, DO, discusses an unmet medical need in the population of patients with urothelial carcinoma.
Christopher J. Hoimes, DO, an assistant professor in the Department of Medicine Division of Hematology and Oncology at the School of Medicine and a member of the Genitourinary Malignancies Program at Case Comprehensive Cancer Center, Case Western Reserve University, discusses an unmet medical need in the population of patients with urothelial carcinoma.
Patients with urothelial carcinoma who are cisplatin-ineligible represent a population of unmet need. At this time, cisplatin-combination chemotherapy is the recommended treatment, but many patients are not eligible for this therapy. The therapeutic options for these patients are limited, as well, notes Hoimes.
